GT
NBIX icon

Greenleaf Trust’s Neurocrine Biosciences NBIX Stock Holding History

Greenleaf Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
+1,993
New +$296K ﹤0.01% 647
2026
Q1 		– Sell
-1,475
Closed -$209K – 841
2025
Q4 		$209K Buy
+1,475
New +$214K ﹤0.01% 783

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Greenleaf Trust's NBIX Position: Q2 2026 in Review

Greenleaf Trust opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,993 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #647 among its holdings. This is a return to the name: Greenleaf Trust previously reported a position in NBIX as recently as Q4 2025.

Greenleaf Trust first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Greenleaf Trust held 1,993 shares of Neurocrine Biosciences worth $336K as of Q2 2026.
  • Neurocrine Biosciences was a new Greenleaf Trust position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Greenleaf Trust's portfolio in Q2 2026, its #647 holding.
  • Greenleaf Trust first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.